Harmonisation of short-term in vitro culture for the expansion of antigen-specific CD8+ T cells with detection by ELISPOT and HLA-multimer staining

Cancer Immunology, Immunotherapy

Volumn 63, Issue 11, 2014, Pages 1199-1211

  Chudley, Lindsey ^a   McCann, Katy J ^a   Coleman, Adam ^a   Cazaly, Angelica M ^a   Bidmon, Nicole ^b   Britten, Cedrik M ^b   van der Burg, Sjoerd H ^c   Gouttefangeas, Cecile ^d   Jandus, Camilla ^e   Laske, Karoline ^d   Maurer, Dominik ^f   Romero, Pedro ^e   Schröder, Helene ^b   Stynenbosch, Linda F M ^c   Walter, Steffen ^f   Welters, Marij J P ^c   Ottensmeier, Christian H ^a,g  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF TÜBINGEN   (Germany)

^e LUDWIG INSTITUTE FOR CANCER RESEARCH   (Switzerland)

^f IMMATICS BIOTECHNOLOGIES GMBH   (Germany)

^g UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

ELISPOT; Harmonisation; In vitro stimulation; Inter laboratory testing; Multimer; T cell

Indexed keywords

HLA ANTIGEN;

CD8+ T LYMPHOCYTE; CHEMISTRY; CLINICAL TRIAL; CYTOLOGY; ENZYME LINKED IMMUNOSPOT ASSAY; GERMANY; GREAT BRITAIN; HUMAN; IMMUNOLOGY; LABORATORY TEST; MONONUCLEAR CELL; MULTICENTER STUDY; NETHERLANDS; PROCEDURES; REPRODUCIBILITY; STAINING; SWITZERLAND;

CD8-POSITIVE T-LYMPHOCYTES; CLINICAL LABORATORY TECHNIQUES; ENZYME-LINKED IMMUNOSPOT ASSAY; GERMANY; GREAT BRITAIN; HLA ANTIGENS; HUMANS; LEUKOCYTES, MONONUCLEAR; NETHERLANDS; REPRODUCIBILITY OF RESULTS; STAINING AND LABELING; SWITZERLAND;

EID: 84939876111     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-014-1593-0     Document Type: Article

References (24)

1. Boaz MJ, Hayes P, Tarragona T, Seamons L, Cooper A, Birungi J, Kitandwe P, Semaganda A, Kaleebu P, Stevens G, Anzala O, Farah B, Ogola S, Indangasi J, Mhlanga P, Van Eeden M, Thakar M, Pujari A, Mishra S, Goonetilleke N, Moore S, Mahmoud A, Sathyamoorthy P, Mahalingam J, Narayanan PR, Ramanathan VD, Cox JH, Dally L, Gill DK, Gilmour J (2009) Concordant proficiency in measurement of T-cell immunity in human immunodeficiency virus vaccine clinical trials by peripheral blood mononuclear cell and enzyme-linked immunospot assays in laboratories from three continents. Clin Vaccine Immunol 16:147–155
2. Schloot NC, Meierhoff G, Karlsson Faresjö M, Ott P, Putnam A, Lehmann P, Gottlieb P, Roep BO, Peakman M, Tree T (2003) Comparison of cytokine ELISpot assay formats for the detection of islet antigen autoreactive T cells. Report of the third immunology of diabetes society T-cell workshop. J Autoimmun 21:365–376
3. Scheibenbogen C, Romero P, Rivoltini L, Herr W, Schmittel A, Cerottini JC, Woelfel T, Eggermont AM, Keilholz U (2000) Quantitation of antigen-reactive T cells in peripheral blood by IFNgamma-ELISPOT assay and chromium-release assay: a four-centre comparative trial. J Immunol Methods 244:81–89
4. Smith SG, Joosten SA, Verscheure V, Pathan AA, McShane H, Ottenhoff TH, Dockrell HM, Mascart F (2009) Identification of major factors influencing ELISpot-based monitoring of cellular responses to antigens from Mycobacterium tuberculosis. PLoS ONE 4:e7972
5. Cox, J. H., Ferrari, G., Kalams, S. A., Lopaczynski, W., Oden, N., D’souza, M. P., Group, E. C. S (2005) Results of an ELISPOT proficiency panel conducted in 11 laboratories participating in international human immunodeficiency virus type 1 vaccine trials. AIDS Res Hum Retroviruses 21:68–81
6. Mander A, Gouttefangeas C, Ottensmeier C, Welters MJ, Low L, van der Burg SH, Britten CM (2010) Serum is not required for ex vivo IFN-gamma ELISPOT: a collaborative study of different protocols from the European CIMT Immunoguiding Program. Cancer Immunol Immunother 59:619–627
7. Janetzki S, Panageas KS, Ben-Porat L, Boyer J, Britten CM, Clay TM, Kalos M, Maecker HT, Romero P, Yuan J, Kast WM, Hoos A (2008) Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother 57:303–315
8. Filbert H, Attig S, Bidmon N, Renard BY, Janetzki S, Sahin U, Welters MJ, Ottensmeier C, van der Burg SH, Gouttefangeas C, Britten CM (2013) Serum-free freezing media support high cell quality and excellent ELISPOT assay performance across a wide variety of different assay protocols. Cancer Immunol Immunother 62:615–627
9. Janetzki S, Price L, Britten CM, van der Burg SH, Caterini J, Currier JR, Ferrari G, Gouttefangeas C, Hayes P, Kaempgen E, Lennerz V, Nihlmark K, Souza V, Hoos A (2010) Performance of serum-supplemented and serum-free media in IFNgamma Elispot Assays for human T cells. Cancer Immunol Immunother 59:609–618
10. Britten CM, Janetzki S, Ben-Porat L, Clay TM, Kalos M, Maecker H, Odunsi K, Pride M, Old L, Hoos A, Romero P (2009) Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium. Cancer Immunol Immunother 58:1701–1713
11. Britten CM, Gouttefangeas C, Welters MJ, Pawelec G, Koch S, Ottensmeier C, Mander A, Walter S, Paschen A, Muller-Berghaus J, Haas I, Mackensen A, Kollgaard T, Thor Straten P, Schmitt M, Giannopoulos K, Maier R, Veelken H, Bertinetti C, Konur A, Huber C, Stevanovic S, Wolfel T, van der Burg SH (2008) The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8 + T lymphocytes by structural and functional assays. Cancer Immunol Immunother 57:289–302
12. Todryk SM, Pathan AA, Keating S, Porter DW, Berthoud T, Thompson F, Klenerman P, Hill AV (2009) The relationship between human effector and memory T cells measured by ex vivo and cultured ELISPOT following recent and distal priming. Immunology 128:83–91
13. Calarota SA, Foli A, Maserati R, Baldanti F, Paolucci S, Young MA, Tsoukas CM, Lisziewicz J, Lori F (2008) HIV-1-specific T cell precursors with high proliferative capacity correlate with low viremia and high CD4 counts in untreated individuals. J Immunol 180:5907–5915
14. Wherry EJ, Teichgräber V, Becker TC, Masopust D, Kaech SM, Antia R, von Andrian UH, Ahmed R (2003) Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol 4:225–234
15. Chudley L, McCann K, Mander A, Tjelle T, Campos-Perez J, Godeseth R, Creak A, Dobbyn J, Johnson B, Bass P, Heath C, Kerr P, Mathiesen I, Dearnaley D, Stevenson F, Ottensmeier C (2012) DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8(+) T-cell responses and increases PSA doubling time. Cancer Immunol Immunother 61:2161–2170
16. Calarota SA, Baldanti F (2013) Enumeration and Characterization of Human Memory T Cells by Enzyme-Linked Immunospot Assays. Clin Dev Immunol 2013:637649
17. Janetzki S, Britten CM, Kalos M, Levitsky HI, Maecker HT, Melief CJ, Old LJ, Romero P, Hoos A, Davis MM (2009) “MIATA”-minimal information about T cell assays. Immunity 31:527–528
18. Mander A, Chowdhury F, Low L, Ottensmeier CH (2009) Fit for purpose? A case study: validation of immunological endpoint assays for the detection of cellular and humoral responses to anti-tumour DNA fusion vaccines. Cancer Immunol Immunother 58:789–800
19. Russell ND, Hudgens MG, Ha R, Havenar-Daughton C, McElrath MJ (2003) Moving to human immunodeficiency virus type 1 vaccine efficacy trials: defining T cell responses as potential correlates of immunity. J Infect Dis 187:226–242
20. Calarota SA, Chiesa A, Zelini P, Comolli G, Minoli L, Baldanti F (2013) Detection of Epstein-Barr virus-specific memory CD4 + T cells using a peptide-based cultured enzyme-linked immunospot assay. Immunology 139:533–544
21. Godkin AJ, Thomas HC, Openshaw PJ (2002) Evolution of epitope-specific memory CD4(+) T cells after clearance of hepatitis C virus. J Immunol 169:2210–2214
22. Pinder M, Reece WH, Plebanski M, Akinwunmi P, Flanagan KL, Lee EA, Doherty T, Milligan P, Jaye A, Tornieporth N, Ballou R, McAdam KP, Cohen J, Hill AV (2004) Cellular immunity induced by the recombinant Plasmodium falciparum malaria vaccine, RTS, S/AS02, in semi-immune adults in The Gambia. Clin Exp Immunol 135:286–293
23. Restifo NP, Dudley ME, Rosenberg SA (2012) Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 12:269–281
24. Widenmeyer M, Griesemann H, Stevanović S, Feyerabend S, Klein R, Attig S, Hennenlotter J, Wernet D, Kuprash DV, Sazykin AY, Pascolo S, Stenzl A, Gouttefangeas C, Rammensee HG (2012) Promiscuous survivin peptide induces robust CD4+ T-cell responses in the majority of vaccinated cancer patients. Int J Cancer 131:140–149